Clinical and Angiographic Outcomes Comparison of Patients With Left Main Vs Non-Left Main Bifurcation Lesions Treated With Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents

被引:0
|
作者
Vergara, Ruben [1 ]
Valenti, Renato [1 ]
Migliorini, Angela [1 ]
Ciabatti, Michele [1 ]
De Gregorio, Maria Grazia [1 ]
Taborchi, Giulia [1 ]
Morini, Sofia [1 ]
Rondine, Roberto [1 ]
Martone, Raffaelle [1 ]
Antoniucci, David [1 ]
机构
[1] Careggi Hosp, Div Cardiol, Viale Pieraccini 17, I-50134 Florence, Italy
关键词
coronary bifurcation lesions; drug-eluting stents; left main bifurcation; percutaneous coronary intervention; STRATEGY; 1ST;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. It is not clear if differences exist about treating left main bifurcation (LMB) and non-left main bifurcation (non-LMB) lesions by means of percutaneous coronary intervention (PCI). Methods. We prospectively analyzed all consecutive patients treated at our center for bifurcation lesions from January 1, 2011 to December 31, 2015, including acute myocardial infarction (MI) and cardiogenic shock, and compared the angiographic and clinical outcomes of patients with LMB and non-LMB lesions treated with PCI and second-generation drug-eluting stent (2G-DES) implantation. The primary endpoint was the major adverse cardiac event (MACE) composite, including MI, clinically indicated target-vessel revascularization (TVR), and cardiac death (CD) at 2-year follow-up. We also compared the angiographic patency of the vessel, which was a composite of the restenosis-reocclusion (RR) rate. Results. Out of 1081 patients (1368 bifurcations), a total of 320 patients had LMB (29%). Overall, procedural success was 98.4%. Clinical follow-up rate was 100%. Angiographic follow-up rate was 83.7%. No differences were seen regarding the primary endpoint of all MACE (17.8% in LMB vs 18.0% in non-LMB; P>.99), MI rate (4.3% in LMB vs 2.9% in non-LMB; P=.20), and CD (8.7% in LMB vs 5.8% in non-LMB; P=.08). The overall RR rate was 11.8%, with 5% RR rate in the LMB group (16/320 lesions) and 9.7% RR rate in the non-LMB group (102/1048 lesions); P<.01. The LMB group had a better TVR rate (5.0% vs 9.4% in the non-LMB group; P=.01). Conclusion. PCI with 2G-DES for LMB has better target-vessel patency and TVR rates when compared with non-LMB lesions, without clinical differences in terms of 2-year clinical outcomes.
引用
收藏
页码:443 / 446
页数:4
相关论文
共 50 条
  • [41] Comparison of the Efficacy of Drug-eluting Stents Versus Bare-metal Stents for the Treatment of Left Main Coronary Artery Disease
    Wang, Xiao-Zeng
    Xu, Kai
    Li, Yi
    Jing, Quan-Min
    Liu, Hai-Wei
    Zhao, Xin
    Wang, Geng
    Wang, Bin
    Ma, Ying-Yan
    Chen, Shao-Liang
    Han, Ya-Ling
    CHINESE MEDICAL JOURNAL, 2015, 128 (06) : 721 - 726
  • [42] Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents
    Ferenc, Miroslaw
    Buettner, Heinz Joachim
    Gick, Michael
    Comberg, Thomas
    Rothe, Juergen
    Khoury, Firas
    Valina, Christian
    Toma, Aurel
    Kuebler, Piotr
    Riede, Florian
    Neumann, Franz-Josef
    CLINICAL RESEARCH IN CARDIOLOGY, 2016, 105 (03) : 230 - 238
  • [43] Mid-Term Results and Costs of Coronary Artery Bypass vs Drug-Eluting Stents for Unprotected Left Main Coronary Artery Disease
    Shimizu, Tsuyoshi
    Ohno, Takayuki
    Ando, Jiro
    Fujita, Hideo
    Nagai, Ryozo
    Motomura, Noboru
    Ono, Minoru
    Kyo, Shunei
    Takamoto, Shinichi
    CIRCULATION JOURNAL, 2010, 74 (03) : 449 - 455
  • [44] Comparison of clinical outcomes between first-generation and second-generation drug-eluting stents in type 2 diabetic patients
    Jeong, Han Saem
    Cho, Jae Young
    Kim, Eun Ji
    Yu, Cheol Woong
    Ahn, Chul-Min
    Park, Jae Hyoung
    Hong, Soon Jun
    Lim, Do-Sun
    CORONARY ARTERY DISEASE, 2013, 24 (08) : 676 - 683
  • [45] The Impact of Anemia Severity on Angiographic and Clinical Outcomes following Percutaneous Coronary Intervention with Drug-eluting Stents in Asian Population
    Park, Ji Young
    Rha, Seung Woon
    Choi, Jae Woong
    Ryu, Sung Kee
    Choi, Byoung Geol
    Choi, Se Yeon
    Im, Sung Il
    Kim, Sun Won
    Na, Jin Oh
    Han, Seong Woo
    Choi, Cheol Ung
    Lim, Hong Euy
    Kim, Jin Won
    Kim, Eung Ju
    Park, Chang Gyu
    Seo, Hong Seog
    Oh, Dong Joo
    CIRCULATION, 2012, 126 (21)
  • [46] Drug-Eluting Stent for Left Main Coronary Artery Disease The DELTA Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Treatment
    Chieffo, Alaide
    Meliga, Emanuele
    Latib, Azeem
    Park, Seung-Jung
    Onuma, Yoshinobu
    Capranzano, Piera
    Valgimigli, Marco
    Jegere, Sanda
    Makkar, Raj R.
    Palacios, Igor F.
    Kim, Young-Hak
    Buszman, Pawel E.
    Chakravarty, Tarun
    Sheiban, Imad
    Mehran, Roxana
    Naber, Christoph
    Margey, Ronan
    Agnihotri, Arvind
    Marra, Sebastiano
    Capodanno, Davide
    Leon, Martin B.
    Moses, Jeffrey W.
    Fajadet, Jean
    Lefevre, Thierry
    Morice, Marie-Claude
    Erglis, Andrejs
    Tamburino, Corrado
    Alfieri, Ottavio
    Serruys, Patrick W.
    Colombo, Antonio
    JACC-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (07) : 718 - 727
  • [47] Impact of PCI Appropriateness in the Long-Term Outcomes of Consecutive Patients Treated With Second-Generation Drug-Eluting Stents
    Seixas, Ana Cristina
    Sousa, Amanda
    Costa, Jose de Ribamar, Jr.
    Moreira, Adriana Costa
    Costa, Ricardo
    Damiani, Lucas
    Neto, Cantidio Campos
    Maldonado, Galo
    Cano, Manuel
    Eduardo Sousa, J.
    JOURNAL OF INVASIVE CARDIOLOGY, 2017, 29 (09) : 290 - 296
  • [48] Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study)
    Mario Iannaccone
    Umberto Barbero
    Michele De Benedictis
    Yoichi Imori
    Giorgio Quadri
    Daniela Trabattoni
    Nicola Ryan
    Giuseppe Venuti
    Andrea Montabone
    Wojciech Wojakowski
    Andrea Rognoni
    Gerard Helft
    Radoslaw Parma
    Leonardo De Luca
    Michele Autelli
    Giacomo Boccuzzi
    Alessio Mattesini
    Christian Templin
    Enrico Cerrato
    Wojciech Wańha
    Grzegorz Smolka
    Zenon Huczek
    Francesco Tomassini
    Bernardo Cortese
    Davide Capodanno
    Alaide Chieffo
    Ivan Nuñez-Gil
    Sebastiano Gili
    Antonia Bassignana
    Carlo di Mario
    Baldassarre Doronzo
    Pierluigi Omedè
    Maurizio D’Amico
    Delio Tedeschi
    Ferdinando Varbella
    Thomas Luscher
    Imad Sheiban
    Javier Escaned
    Mauro Rinaldi
    Fabrizio D’Ascenzo
    BMC Cardiovascular Disorders, 20
  • [49] Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry
    Buchanan, Gill Louise
    Chieffo, Alaide
    Bernelli, Chiara
    Montorfano, Matteo
    Carlino, Mauro
    Latib, Azeem
    Figini, Filippo
    Giannini, Francesco
    Durante, Alessandro
    Ielasi, Alfonso
    Castelli, Alfredo
    Colombo, Antonio
    EUROINTERVENTION, 2013, 9 (07) : 809 - 816
  • [50] Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study)
    Iannaccone, Mario
    Barbero, Umberto
    De Benedictis, Michele
    Imori, Yoichi
    Quadri, Giorgio
    Trabattoni, Daniela
    Ryan, Nicola
    Venuti, Giuseppe
    Montabone, Andrea
    Wojakowski, Wojciech
    Rognoni, Andrea
    Helft, Gerard
    Parma, Radoslaw
    De Luca, Leonardo
    Autelli, Michele
    Boccuzzi, Giacomo
    Mattesini, Alessio
    Templin, Christian
    Cerrato, Enrico
    Wanha, Wojciech
    Smolka, Grzegorz
    Huczek, Zenon
    Tomassini, Francesco
    Cortese, Bernardo
    Capodanno, Davide
    Chieffo, Alaide
    Nunez-Gil, Ivan
    Gili, Sebastiano
    Bassignana, Antonia
    di Mario, Carlo
    Doronzo, Baldassarre
    Omede, Pierluigi
    D'Amico, Maurizio
    Tedeschi, Delio
    Varbella, Ferdinando
    Luscher, Thomas
    Sheiban, Imad
    Escaned, Javier
    Rinaldi, Mauro
    D'Ascenzo, Fabrizio
    BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01) : 225